BioSpace

BioSpace
  • 0,0 (0)
  • Science de la vie
  • Chaque semaine

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

  1. From fragile skin to living medicine: Lessons from RDEB

    -4 j

    From fragile skin to living medicine: Lessons from RDEB

    In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future.   Host   Jennifer C. Smith-Parker, Director of Insights, BioSpace   Guests   Mark Lowdell, CSO & Co-Founder, INmuneBio Inc   Vishwas Seshadri, CEO & Director, Abeona Therapeutics   Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    22 min
  2. Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

    -5 j

    Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

    Moderna’s mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisory committee meeting for June 18. In documents released ahead of that meeting, the FDA and Moderna seem to have reached alignment, though the agency did flag certain data gaps for advisors to review. Biotech IPOs are off the charts—literally. This past month has seen not one but two record-setting public debuts. First there was Kailera Therapeutics, which hit the market with $625 million in April, outpacing Moderna’s 2018 IPO of $600 million. And now we have Parabilis Medicines, which last week dethroned Kailera as the largest biotech IPO of all time, with $670 million. Meanwhile, the number of employees laid off spiked by almost 50% year-over-year in May, though that jump is mostly due to significant cuts at Takeda and BioNTech. Genentech also made a big change last week. Eli Lilly continued its dealmaking spree with AlzeCure, striking a licensing agreement worth up to $1 billion centering on a small-molecule asset for Alzheimer’s disease. But the bigger Lilly news in the past week was clinical results that show promise for the pharma’s $2.3 billion acquisition of Ajax Therapeutics in April. Earlier this month, the FDA held a public session to glean feedback regarding the Commissioner’s National Priority Voucher program, in which several groups called for a temporary pause to the pilot, citing concerns about transparency and political involvement. While the future of that program hangs in the balance, two voucher holders got updates this week. First, Sanofi’s diabetes drug Tzield was greenlit for older kids and teenagers, though it’s unclear whether a voucher was associated with the approval. Meanwhile, Disc Medicine’s rejected rare disease drug bitopertin appears to be back on track, with the biotech announcing last week that the FDA will allow its current Phase 3 trial to support another regulatory filing.

    26 min
  3. Portugal, Spain and the new biotech frontier

    10 juin

    Portugal, Spain and the new biotech frontier

    In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc. We examine the rise of Southern Europe’s biotech ecosystem—from Portugal’s efforts to turn strong science into startups to Spain’s growing depth of capital and talent—and what it will take for the region to compete globally. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Hannah Franklin, Associate, Biovance Capital Pablo Gabriel Cironi Lopez, Director, Life Science Investment, Caixa Capital Risc Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    21 min
  4. Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

    10 juin

    Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

    Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide—not just for weight loss but also for other indications. Obesity rival Novo Nordisk, meanwhile, held a dinner, during which executives may have convinced analysts that the company is turning a corner after a rough couple of years. Also check out ADA updates from Roche and partner Zealand Pharma, Boehringer Ingleheim, Pfizer (touting results from its Metsera buy), AstraZeneca, Kailera Therapeutics and more. Outside of ADA, the biggest news of the past week came on Tuesday with GSK striking the biggest traditional pharma/biotech M&A of the year so far with its $10.6 billion acquisition of oncology focused Nuvalent Bio. And on Monday, J&J notched a smaller deal, buying out Firefly Bio for $1B. These deals add to continued uptick in M&A seen in biopharma this year, with much of that momentum being driven by Eli Lilly and its GLP-1 cash. At an FDA listening meeting last week on the Commissioner’s National Priority Voucher program, the agency heard multiple calls to pause it. Confusion also still persists around all of the new rare disease pathways, including the new plausible mechanism framework.

    25 min
  5. Rethinking hair loss treatment

    3 juin

    Rethinking hair loss treatment

    In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Daniel Gil, CEO, Pelage Pharmaceuticals Francisco Ramírez-Valle, Senior Vice President, Immunology Discovery, Eli Lilly Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    22 min
  6. ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

    3 juin

    ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

    At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics’ Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso’s clinical trial in China will hold up in a global population. Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China’s Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We’ll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

    27 min
  7. France’s biotech ecosystem: science, capital and scale

    28 mai

    France’s biotech ecosystem: science, capital and scale

    In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Ksenija Pavletic, Partner and Chief Commercial Officer, Jeito Capital Thierry Laugel, Managing Partner, Kurma Partners Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    21 min
  8. Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

    27 mai

    Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

    Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine development with three separate buys in the space. Outside of vaccines, Lilly scooped up preclinical biotech Engage Bio for $202 million and teamed up with AI company Collaborative Drug Discovery for its life sciences data management solutions. These deals and Lilly’s skyrocketing revenue pushed the Indianapolis-based company to the top of IDEA Pharma’s list of best inventors and innovators. Lilly also continues to make headlines for its impressive data readouts, especially in the weight-loss space that it now reigns supreme. Last week, Lilly announced that next-gen asset retatrutide led to weight loss of 70 pounds, or 28.3% at 80 weeks, setting a new benchmark for the space. Moderna also made news this week with a surprising uptick in its share price that analysts are attributing to the so-called “fear trade” that is rising amid reports of a cluster of cases of hantavirus. Moderna also announced that its mRNA flu shot—initially turned away from the FDA but later accepted for review—will be discussed at an advisory committee on June 18. The annual conference of the American Society of Clinical Oncology starts on Friday in Chicago, where all eyes will be on Revolution Medicines’ investigational pancreatic cancer pill and Akeso’s Phase 3 trial HARMONi-6 for its Summit Therapeutics-partnered PD-1/VEGF bispecific ivonescimab. Finally, sign up for BioPharma Executive to receive this week’s special edition breaking down executive compensation packages across the biggest pharmas.

    25 min
Tout afficher (240)

À propos

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Informations

  • Création
    BioSpace
  • Années d’activité
    2023 - 2026
  • Épisodes
    240
  • Classification
    Tous publics
  • Copyright
    © 2026 BioSpace
  • Site web de l’émission
    BioSpace

Vous aimeriez peut‑être aussi